With significant upside potential, Wave Life Sciences Ltd. (NASDAQ:WVE) secures a spot on our list of the best small-cap biotech stocks to buy according to analysts.
On November 13, 2025, Jefferies analyst Roger Song noted that Wave Life Sciences Ltd.’s competitive positioning is improving, with Korro Bio’s KRRO-110 reporting failure to produce protective levels of corrected protein in a Phase 1/2 AATD trial. This led to the discontinuation of Korro Bio’s lead asset. The analyst keeps a “Buy” rating with a $26 price target on Wave Life Sciences.
Meanwhile, Wave Life Sciences Ltd. reported its Q3 results on November 10, 2025, where its $7.6 million revenue missed analyst forecasts of $12.89 million. At the same time, the company reduced its net loss from $61.8 million in Q3 2024 to $53.9 million, despite R&D and G&A expenses increasing to $45.9 million and $18.1 million. Increased costs were related to the company’s ongoing investment in clinical programs, particularly the WVE-007 trial.
Furthermore, the quarter saw Wave Life Sciences Ltd. reporting a cash runway extended through Q2 2027. This will help ensure operational continuity and funding for ongoing clinical and development initiatives. Looking ahead, the company seems well-positioned to advance its clinical-stage pipeline, as it remains focused on RNA-based therapies and strategic expansion of its product development programs.
Wave Life Sciences Ltd., a clinical-stage biotech company, develops and commercializes ribonucleic acid (RNA) medicines with the help of its proprietary PRISM discovery and drug development platform.
READ NEXT: 7 Best Oil and Gas Penny Stocks to Buy According to Analysts and Billionaire Jacob Rothschild’s RIT Capital Partners: 9 Stocks with Huge Upside Potential.
